Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 12/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28569496 | 1.00 | ATF4 (0.67) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL28569497 | 1.00 | ATF4 (0.67) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL30054459 | 1.00 | ATF4 (0.67) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL28580887 | 0.91 | ATF4 (0.63) | ATF4LMNA | |
| SCHEMBL28580886 | 0.91 | ATF4 (0.63) | ATF4LMNA | |
| SCHEMBL28567281 | 0.91 | ATF4 (0.60) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL28567286 | 0.91 | ATF4 (0.60) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL30883092 | 0.91 | ATF4 (0.60) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16082976 | 0.91 | ATF4 (0.78) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL23455918 | 0.89 | ATF4 (0.69) | ATF4LMNARAB9AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230042881-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042881-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885LMNA 4342/4885RAB9A 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.